Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients

Çetin Ordu; Kezban N. Pilanci; Nilüfer Avcı; İbrahim Yıldız; Gül Alço; Özkan Demirhan; Ülkühan I. Köksal; Filiz Elbüken; Coskun Tecimer; Gökhan Demir

doi:10.5114/wo.2016.60069

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2016
vol. 20

Send email

Copy url:

abstract:

Original paper

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients

Çetin Ordu

,

Kezban N. Pilanci

,

Nilüfer Avcı

,

İbrahim Yıldız

,

Gül Alço

,

Özkan Demirhan

,

Ülkühan I. Köksal

,

Filiz Elbüken

,

Coskun Tecimer

,

Gökhan Demir

Contemp Oncol (Pozn) 2016; 20 (2): 147-152

DOI: https://doi.org/10.5114/wo.2016.60069

Online publish date: 2016/06/14

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Ordu Ç, Pilanci K, Avcı N, et al. Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients. Contemporary Oncology/Współczesna Onkologia. 2016;20(2):147-152. doi:10.5114/wo.2016.60069.

APA

Ordu, Ç., Pilanci, K., Avcı, N., Yıldız, İ., Alço, G.,  & Demirhan, Ö. et al. (2016). Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients. Contemporary Oncology/Współczesna Onkologia, 20(2), 147-152. https://doi.org/10.5114/wo.2016.60069

Chicago

Ordu, Çetin, Kezban N. Pilanci, Nilüfer Avcı, İbrahim Yıldız, Gül Alço, Özkan Demirhan,  and Ülkühan I. Köksal et al. 2016. "Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients". Contemporary Oncology/Współczesna Onkologia 20 (2): 147-152. doi:10.5114/wo.2016.60069.

Harvard

Ordu, Ç., Pilanci, K., Avcı, N., Yıldız, İ., Alço, G., Demirhan, Ö., Köksal, Ü., Elbüken, F., Tecimer, C.,  and Demir, G. (2016). Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients. Contemporary Oncology/Współczesna Onkologia, 20(2), pp.147-152. https://doi.org/10.5114/wo.2016.60069

MLA

Ordu, Çetin et al. "Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients." Contemporary Oncology/Współczesna Onkologia, vol. 20, no. 2, 2016, pp. 147-152. doi:10.5114/wo.2016.60069.

Vancouver

Ordu Ç, Pilanci K, Avcı N, Yıldız İ, Alço G, Demirhan Ö et al. Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients. Contemporary Oncology/Współczesna Onkologia. 2016;20(2):147-152. doi:10.5114/wo.2016.60069.

PlumX metrics:

Aim of the study: Sunitinib-related side effects may develop as a result of the pharmacokinetic pathway affects the of the drug.

Material and methods: Data on mRCC patients were obtained from the hospital archives. Outcomes of patients were evaluated in terms of related prognostic factors, sunitinib adverse events during the treatment, and two different sunitinib dosing schedules.

Results: Seventy patients diagnosed with mRCC and treated with sunitinib were analyzed for prognostic factors and survival rates. During the mean follow-up of 33.5 months, 38 (54%) patients were alive and 32 (46%) patients died. The median time of overall survival (OS) and progression-free survival (PFS) was 27 months (12–61) and 19 months (5–45), respectively. In univariate analysis, good prognostic risk group according to the Memorial Sloan-Kettering Cancer Center (MSKCC), hypothyroidism as sunitinib toxicity and patients on sunitinib treatment more than 1 year were favorable prognostic factors for OS. Leukopenia and fatigue as sunitinib toxicity were poor prognostic factors for OS. PFS and OS of the patients were not significantly different when we compared intermittent (4/2) vs. continuous treatment dosing schedules.

Conclusions: As a result of this trial, having hypothyroidism as an adverse effect of sunitinib was a favorable prognostic factor for OS and PFS in mRCC patients. It was also found that 4/2 and continuous dosing schedules of sunitinib did not give rise to different outcomes in mRCC patients.

keywords:

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients

Çetin Ordu , Kezban N. Pilanci , Nilüfer Avcı , İbrahim Yıldız , Gül Alço , Özkan Demirhan , Ülkühan I. Köksal , Filiz Elbüken , Coskun Tecimer , Gökhan Demir

metastatic renal cell carcinoma, prognostic factors, dosing schedule, sunitinib toxicity

Çetin Ordu

,

Kezban N. Pilanci

,

Nilüfer Avcı

,

İbrahim Yıldız

,

Gül Alço

,

Özkan Demirhan

,

Ülkühan I. Köksal

,

Filiz Elbüken

,

Coskun Tecimer

,

Gökhan Demir